The Role of A2E in RPE Atrophy
About the Research Project
Program
Award Type
Standard
Award Amount
$150,000
Active Dates
April 01, 2003 - September 30, 2005
Grant ID
M2003043
Summary
It has long been suspected that macular pigments composed of the carotenoids lutein and zeaxanthin protect the retina both by filtering high-energy blue light and by serving an antioxidant function, but the specific photochemical reactions that these nutrients protect against remain unknown. Dr. Sparrow has proposed that the lutein and zeaxanthin in retinal pigment epithelium (RPE) cells protect against the light-induced oxidative changes (photooxidation) of an aging fluorescent compound (A2E), which accumulates in these cells. She has also hypothesized that lutein and zeaxanthin suppress similar photooxidative changes in the A2E precursor molecule called A2-PE. In earlier work, she demonstrated that the excitation of A2E with blue light leads to the generation of singlet oxygen and that these reactive oxygens are subsequently inserted into the A2E molecule (photooxidation), creating a very reactive derivative with the potential for damaging cellular macromolecules such as protein and DNA. Her goal now is to demonstrate that the precursor A2-PE undergoes the same photooxidative change and to determine whether lutein and zeaxanthin protect against the photooxidation of A2E and A2-PE. Then, her team will test the assumption that these carotenoids prevent photooxidative changes in A2E and A2-PE through their ability to deactivate the highly reactive oxygen species (singlet oxygen). They will compare lutein and zeaxanthin’s antioxidant capabilities and determine whether these nutrients can act in synergy with vitamin E and vitamin C, other natural antioxidants that are present in these cells. The long-term goal of this work is to develop therapies that would counteract the photochemical events initiated by A2E. This project is a continuation of an MDR-funded study that began in 2001.
Grants
Related Grants
Macular Degeneration Research
The Novel Role of an Intracellular Nuclear Receptor in AMD Pathogenesis
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Neetu Kushwah, PhD
Macular Degeneration Research
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Krishna Singh, PhD
Macular Degeneration Research
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Shintaro Shirahama, MD, PhD